Sign up to save your podcasts
Or
Share Turn Raw Tech Into Revenue: Eugene Buff’s 30-Year Playbook for Open Innovation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Turn Raw Tech Into Revenue: Eugene Buff’s 30-Year Playbook for Open Innovation
For 30+ years, Eugene Buff has been the behind-the-scenes “bridge” between breakthrough science and the companies that actually bring it to market—from university tech transfer offices drowning in inventions to global corporates hunting for the next edge. He’s a MD/PhD geneticist, a former Harvard Medical School researcher whose papers still get cited… and the rare operator who walked away from NIH funding to pursue commercialization full-time.
In this conversation with Haggai Klorman Eraqi, Eugene tells the story of how he realized the Nobel line was “too long,” and reinvented himself as an innovation strategist who helps organizations answer the hard question: Is this worth building—or should we kill it fast?
You’ll hear:
- Why you’re not commercializing inventions—you’re solving problems
- The surprising reason Eugene’s default approach is to try to kill the project
- What “open innovation” really means
- How strategic partnerships, licensing, sponsored research, and venture differ
- When getting a patent is the wrong move
If you’re building “deep tech,” spinning out IP, or trying to land a corporate partner without getting crushed by bureaucracy—this episode is for you.
Check out the full episode notes, transcripts, and all links on Substack:
👉 https://aggaeus.com/
CONNECT WITH EUGENE BUFF
CONNECT WITH HAGGAI
FOLLOW AGGAEUS
TikTok
YouTube
SUBSCRIBE TO THE PODCAST
Apple Podcasts
SPONSORS
Kardz.Biz — “A business card too good to give away.”
INQUIRIES
💼 Sponsorships / Business: [email protected]
🎙 Podcast: DM via Instagram
Some links may earn affiliate commissions. Offers, terms, and availability may change without notice.
Aggaeus content is for informational and educational purposes only and should not be considered legal, business, investment, or tax advice. You should conduct your own research and consult qualified professionals before making any decisions.
We may feature companies, products, or entities in which Aggaeus, its affiliates, or the author have invested or may invest, or with which they have had, have, or may have a financial, professional, or other relationship.
#OpenInnovation #DeepTech #TechTransfer #StartupStrategy #Innovation
View all episodes
By Hosted by Haggai Klorman-EraqiFor 30+ years, Eugene Buff has been the behind-the-scenes “bridge” between breakthrough science and the companies that actually bring it to market—from university tech transfer offices drowning in inventions to global corporates hunting for the next edge. He’s a MD/PhD geneticist, a former Harvard Medical School researcher whose papers still get cited… and the rare operator who walked away from NIH funding to pursue commercialization full-time.
In this conversation with Haggai Klorman Eraqi, Eugene tells the story of how he realized the Nobel line was “too long,” and reinvented himself as an innovation strategist who helps organizations answer the hard question: Is this worth building—or should we kill it fast?
You’ll hear:
- Why you’re not commercializing inventions—you’re solving problems
- The surprising reason Eugene’s default approach is to try to kill the project
- What “open innovation” really means
- How strategic partnerships, licensing, sponsored research, and venture differ
- When getting a patent is the wrong move
If you’re building “deep tech,” spinning out IP, or trying to land a corporate partner without getting crushed by bureaucracy—this episode is for you.
Check out the full episode notes, transcripts, and all links on Substack:
👉 https://aggaeus.com/
CONNECT WITH EUGENE BUFF
CONNECT WITH HAGGAI
FOLLOW AGGAEUS
TikTok
YouTube
SUBSCRIBE TO THE PODCAST
Apple Podcasts
SPONSORS
Kardz.Biz — “A business card too good to give away.”
INQUIRIES
💼 Sponsorships / Business: [email protected]
🎙 Podcast: DM via Instagram
Some links may earn affiliate commissions. Offers, terms, and availability may change without notice.
Aggaeus content is for informational and educational purposes only and should not be considered legal, business, investment, or tax advice. You should conduct your own research and consult qualified professionals before making any decisions.
We may feature companies, products, or entities in which Aggaeus, its affiliates, or the author have invested or may invest, or with which they have had, have, or may have a financial, professional, or other relationship.
#OpenInnovation #DeepTech #TechTransfer #StartupStrategy #Innovation